NASD · Healthcare · Drug Manufacturers - Specialty & Generic · USA
United Therapeutics Corp is a large cap company (market value between $10 billion and $200 billion) in the Drug Manufacturers - Specialty & Generic industry.
United Therapeutics develops and sells therapies for serious diseases with unmet medical needs, primarily pulmonary arterial hypertension treatments. The company markets multiple formulations of treprostinil, including Tyvaso DPI inhalation powder, Nebulized Tyvaso, Remodulin injection, and Orenitram tablets, along with Adcirca tablets and Unituxin for oncology in the United States and select international markets.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the United Therapeutics Corp stock.
Slightly undervalued: intrinsic value $601.53 per share, market price $543.15, margin of safety 9.7% (as of 2026-10-19).
Discounting its cash flows at 8.2% (average of 3 methods) values the shares at $601.53; the price of $543.15 is 10% below that value, and 79% of that value comes from beyond year five.
Leak Score: 55/100 on 10 of 12 signals (Weak Signal).
17 more funds hold it; the full list is part of the paid plan.
All 84 Drug Manufacturers - Specialty & Generic stocks
10 more in this industry show a wider margin of safety.
UTHR is slightly undervalued (as of the 2026-10-19 close). Discounting its cash flows at 8.2% (average of 3 methods) values the shares at $601.53; the price of $543.15 is 10% below that value, and 79% of that value comes from beyond year five.
$601.53 per share (as of the 2026-10-19 close), against a market price of $543.15. That is a margin of safety of 9.7%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
55 out of 100, which we rate "Weak Signal", on 10 of 12 value investing signals.